remdesivir for COVID-19 - living meta-analysis of clinical studies

meta|evidence COVID-19

Living systematic review and meta-analysis

vs. potential COVID-19 treatments
vs. antiviral and associated therapy
vs. remdesivir
vs. control
vs. placebo
vs. standard of care

All
COVID 19 hospitalized
COVID 19 all comers
COVID-19 mild to moderate
COVID-19 severe or critically
COVID 19 outpatients
COVID-19 (hospitalized or not)
COVID-19 prophylaxis (children)
COVID-19 prophylaxis (excluding children)
infections other than COVID-19
Long COVID-19
preventing respiratory virus transmission
root
secondary prevention

Studies
Mapping
Meta-analysis
Excluded 1

table network network 2

display ongoing demontrated benefit only

popup

Norwegian NOR study (remdesivir), 2021 NCT04321616

remdesivir vs. standard of care

COVID 19 all comers

Andreas (NOR-Solidarity), 2021 NCT04321616

remdesivir vs. standard of care

COVID 19 all comers

NIH NIAID ACTT-1, 2020 NCT04280705

remdesivir vs. placebo

COVID 19 hospitalized

Mahajan, 2021

remdesivir vs. standard of care

COVID 19 hospitalized

DisCoVeRy (remdesivir), 2021 NCT04315948

remdesivir vs. standard of care

COVID 19 hospitalized

remdesevir external control, 0

remdesivir vs. standard of care

COVID 19 hospitalized

SOLIDARITY (remdesivir), 2020 NCT04315948

remdesivir vs. standard of care

COVID 19 hospitalized

GS-US-540-5773 (Goldman), 2020 NCT04292899

remdesivir vs. remdesivir

COVID-19 mild to moderate

GS-US-540-5774, 5 days, 2020 NCT04292730

remdesivir vs. standard of care

COVID-19 mild to moderate

GS-US-540-5774, 10 days, 2020 NCT04292730

remdesivir vs. standard of care

COVID-19 mild to moderate

CAP-China (Wang et al.), 2020 NCT04257656

remdesivir vs. placebo

COVID-19 severe or critically

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy -

Extraction panel open

An extraction panel is open